Optimizing Local Treatment in Pemphigus and Pemphigoid: Current Evidence and Unmet Needs - PubMed
6 days ago
- #wound care
- #autoimmune blistering diseases
- #topical treatments
- Autoimmune blistering diseases (AIBDs) like pemphigus vulgaris (PV) and bullous pemphigoid (BP) cause painful erosions and chronic wounds, impacting quality of life.
- Systemic therapies are primary treatments, but local management strategies (wound care, topical therapies) lack standardization.
- Topical corticosteroids, especially clobetasol propionate, are first-line for BP and adjunctive for PV.
- Topical calcineurin inhibitors show promise as steroid-sparing agents but have limited evidence.
- Antiseptics (e.g., chlorhexidine) and topical antibiotics (e.g., mupirocin) may aid infection control in secondary infections.
- Dressing selection (non-adherent, antimicrobial, moisture-retentive) is critical to minimize trauma and promote healing.
- Current evidence supports high-potency corticosteroids for BP and adjunctive use in PV, but more research is needed for antiseptics and advanced dressings.
- Well-designed clinical trials are required to establish evidence-based guidelines for local AIBD management.